Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party.

Journal article

Between May 1988 and March 1995, 359 children with acute myeloid leukaemia (AML) were treated in the MRC AML 10 trial. Three risk groups were identified based on cytogenetics and response to treatment. One hundred and twenty-five children relapsed--103 in the bone marrow only, 12 in the bone marrow combined with other sites, and six had isolated extramedullary relapses (site was not known in four cases). Eighty-seven children received further combination chemotherapy, one all-trans retinoic a...

Expand abstract

Authors: Webb, D; Wheatley, K; Harrison, G; Stevens, R; Hann, I

• Publication status: Published
• Journal: Leukemia
• Volume: 13
• Issue: 1
• Pages: 25-31
• Publication date: 1999-01-01
• DOI: 10.1038/sj/leu/2401254
• EISSN: 1476-5551
• ISSN: 0887-6924
• Language: English
• Keywords: Disease-Free Survival; Tretinoin; Recurrence; Transplantation, Autologous; Clinical Protocols; Antineoplastic Agents; Child; Follow-Up Studies; Great Britain; Adolescent; Acute Disease; Transplantation, Homologous; Leukemia, Myeloid; Bone Marrow Transplantation; Humans; Antineoplastic Combined Chemotherapy Protocols; Survival Analysis